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INTRODUCTION
B cells and autoantibodies are important drivers of autoimmune inflammatory diseases.
Autoantibodies are central in the pathology of systemic lupus erythematosus (SLE) and are postulated to drive inflammation also in idiopathic inflammatory myositis (IIM) [1] . Yet, B cells are also essential in regulating immune reactions by presenting antigens to T cells and by secreting immune modulatory cytokines. SLE patients can display a range of autoantibodies to nuclear antigens including DNA, ribonucleoprotein, and chromatin proteins. IgG-autoantigen immune complexes have been hypothesized to be immune-stimulatory by activation via Fc [2] and toll like receptor (TLR) [3] pathways, and are deposited in tissues causing activation of complement. Peripheral blood B cells in SLE have been reported to be phenotypically and functionally abnormal in several ways [4, 5] ; for example, there is an increased frequency of double negative memory B cells lacking CD27 in circulation [6, 7] . These IgD -CD27double negative memory B cells are associated with disease activity as well as with renal disease in SLE [7] . In addition, extrafollicular maturation processes of B cells have, in mouse models, been shown to have pathogenic relevance in different phases of autoimmune disease [5] . These phenotypic and functional alterations strongly suggest B cells as main drivers of autoimmune pathology in SLE.
Consequently, several B-cell targeting therapies have been evaluated and some have moved forward to clinical development [8] . B-cell depletion by the anti-CD20 targeting monoclonal rituximab is approved for treatment of patients with rheumatoid arthritis and anti-neutrophil cytoplasmic antibody (ANCA)-vasculitis and is commonly used off-lable in several autoimmune conditions, but failed to meet the efficacy end-point in SLE. In contrast, blocking B-cell activating factor BAFF (Belimumab), reducing B-cell survival, represents the only biological drug that is currently approved for treatment of SLE. Blocking BAFF mainly targets mature B cells, but other inhibitors are under clinical development for A proliferation-inducing ligand (APRIL) and its receptor that could also target longlived plasma cells. Other strategies include monoclonal antibodies and chimeric antigen receptor (CAR)-T-cells targeting several B-cell subtypes (CD19, CD20 and CD22 expressing cells) while sparing mature long-lived antibody-secreting plasma cells. Recently, velcade/bortezomib, a small molecule proteasome inhibitor, was shown to deplete plasma cells and ameliorate refractory SLE [9] , although clinical development is hampered by association with adverse events [10] . Other approaches, such as CD40 and CD40L blocking therapies, may also prove useful in regulating B-cell functions in autoimmune diseases. While these efforts are promising, there is presently only a few therapies available for the treatment of patients with SLE and IIM, often resulting in partial responses and only helping a fraction of the patients.
Hence, there is an unmet medical need in B-cell driven autoimmune diseases, including SLE and IIM.
Patient derived primary cells (e.g. xenografts, organoids, tissue slice cultures, short term cell lines) have been explored in vitro for new exploratory treatment strategies for cancer, however such approaches are not commonly used in drug discovery efforts for chronic inflammatory conditions.
Instead, drug development mainly in SLE but also to some degree in IIM (inclusion body myositis and polymyositis) depends primarily on studies of animal models. The clinical relevance of animal models can be questioned [11] , and we believe that phenotypic screens using primary cells from patients are better suited for translational research from bed to benchside and then back to bed, for translational target evaluation.
The Structural Genomics Consortium (www.thesgc.org), a non-profit public-private organization that aim to accelerate discovery of new medicine through open research, has during the last decade developed chemical probes in collaboration with partners from the pharmaceutical industry. These small inhibitory molecules are selective, potent, and are made available to the scientific communitywithout restrictions on research use. The SGC probes target mainly epigenetic regulators, but also other proteins with critical immune functionality are contained within this collection (https://www.thesgc.org/chemical-probes).
I this study, our aim was to screen these chemical probes in a patient-derived primary B-cell assay for functions relevant in autoimmune diseases (SLE and IIM). Thus, we developed an assay using peripheral blood mononuclear cells (PBMCs) from patients and healthy donors and investigated the effect of 43 probes and compounds on induced B-cell maturation and antibody secretion. Our results
show that nine of these novel probes, which inhibit bromodomain family proteins and histone methyl transferases, demonstrate abrogation of B-cell functions to a degree comparable to a positive control, the JAK inhibitor tofacitinib. We also discuss small-molecule targeting of epigenetic regulators as a potiential B-cell modulating therapeutic strategy in systemic autoimmune disease.
MATERIAL AND METHODS

Patients and healthy subjects
Peripheral blood was collected from 20 blood donors including five patients diagnosed with SLE and fulfilling the 1982 revised ACR classification criteria for SLE [12] and/or the SLICC-2012 criteria [13] 
Chemical Probes
A set of 43 chemical probes inhibiting epigenetic regulators, protein kinases and other proteins were tested in this study. The chemical probes are small molecules and met the following criteria: In vitro potency of <100 nM, >30-fold selectivity vs other subfamilies, demonstration of on-target effect in cells at 1 µM (detailed information is available at https://www.thesgc.org/chemical-probes). To validate probe effects, negative control compunds were used when available. Negative (inactive) controls have a similar chemical structure as active probes (Figure 6b ) but do not bind to the primary targets.
Isolation and in vitro culture of peripheral blood mononuclear cells (PBMCs)
PBMCs were isolated from heparinized blood or citrated buffy coat preparations by gradient centrifugation using Ficoll-Paque PLUS density gradient media (GE Healthcare Bioscience). After In a separate set of experiments, PBMCs were cultured for six days in presence or absence of stimulation cocktail as above. On day six of culture, cells were washed with DPBS twice, a new stimulatory cocktail, as well as chemical probes, were added to stimulated cells and plates incubated for a further four days. Cell culture supernatants were collected, and IgG content was determined by ELISA.
Flow cytometry
Cells from triplicate wells were collected and pooled, washed twice with DPBS, stained with LIVE/DEAD® fixable near-IR dead cell marker (ThermoFisher), and stained for surface markers. 
Determination of immunoglobulin concentrations
Immunoglobulins (Ig) in culture supernatants were measured using a human IgG ELISA development kit (Mabtech) according to manufacturer's instructions, or F(ab)2 polyclonal goat anti-human IgM (Jackson Immuno Research) as capture antibody and detection with HRP-conjugated mouse µ-specific anti-human IgM (Southern Biotech, clone SA-DA4).
Statistical analysis
Statistical analysis was performed using the Mann-Whitney U test or the Kruskal-Wallis test.
Differences were considered statistically significant if P<0.05.
RESULTS
Characterization of the B-cell assay
Initially, the assay was evaluated by stimulation of PBMCs from healthy donors (n=3) with rhIL-4, rhIL-10, rhIL-21, rhsCD40L, and CpG (ODN2006) either individually or in combination, and secretion of IgG after six days of culture was assessed by ELISA ( Figure 1a ). Although the level of 
Evaluation of B-cell function and phenotype in patients with SLE and IIM
The assay was thereafter used to analyze the B-cell maturation stage and response to stimulation in PBMCs isolated from five patients with SLE, six patients with IIM andseven healthy donors. Patients with SLE showed a lower total frequency of B cells among lymphocytes in freshly isolated PBMCs as compared to healthy controls (Figure 2a ), and a higher proportion of memory B cells (Figure 2b ).
Despite these basal differences in B-cell phenotype, stimulation induced an accumulation and maturation of B cells in both patients and healthy donors (Figure 2a-c) , and IgG as well as IgM secretion was induced to a similarlevel ( Figure 2d ). Normalization of secreted IgG levels to the B-cell fraction of PBMCs showed similarly that the ability of the B cells to mature and produce IgG did not differ between healthy controls and patients with SLE or IMM (data not shown).
Testing chemical probes and compounds in the B-cell assay using cells from patients with SLE,
IIM and healthy controls
Next, we sought to investigate whether our defined set of chemical probes could affect B-cell phenotype and function in healthy controls and patients. We used a panel of 43 different probes and compounds at one concentration (1 µM or 0.1 µM) in the above described B-cell stimulation assay.
The concentration used in our studies followed recommendations by the provider, based on experiences and results from applying these probes to various cellular assays (demonstrated on-target effect and not associated with toxicity). PBMCs from 20 blood donors including healthy donors (n=7) and patients with SLE (n=5) and IIM (n=8) were pre-incubated with probes before addition of stimuli and cultured for six days. The JAK protein kinase inhibitor tofacitinib was used as a positive control.
The effect of probes was normalized to DMSO vehicle control, and an arbitrary cutoff for effect was set at (average for n=20 donors) >50% reduction of IgG secretion, without overt cytotoxic effects as There was no statistically significant difference of probe effects comparing healthy donors to patient groups. However, we observed a tendency in that inhibitors of methyltransferases reduced the accumulation of B cells, whereas BET inhibitors tended to reduce their maturation into memory cells ( Figure 3b ). All nine probes reduced, to different degrees, the proportion of plasmablasts and IgG secretion, with similar effect as tofacitinib (Figure 3b ). 
Effect of chemical probes on proliferation of B-cell subsets
Evaluating the effect of chemical probes on in vitro matured B cells
Next we sought to investigate whether the probes affect the functionality of already matured B cells.
Hence, we added probes to PBMCs after 6 days of stimulation, allowing B cells to mature into IgG secreting plasmablasts before inhibiting the epigenetic regulators ( Figure 5 ). IgG secretion was induced by cytokines to a level of 4232±1711 ng/ml (Mean±SD n=6) after 6+4 days of stimulation (77±80 ng/ml without stimulation). Bromodomain targeting probes JQ1 and PFI-1 had a clear suppressive effect on IgG secretion in already matured B cells ( Figure 5 ), suppressing by more than 60% on average. UNC1999 showed a variable suppressive effect, while tofacitinib suppressed IgG secretion by 37%.
Investigating the on-target effects of probes by the use of negative control compounds
We then investigated whether the effects by the probes on IgG secretion in the B-cell assay were due to on-target mediated effects by including negative control compounds available for JQ1, UNC1999, UNC0638, GSK591 and OICR-9429. These compounds are similar in structure to the active compounds ( Figure 6b ), but do not bind and inhibit the function of the primary target protein. We were able to confirm on-target effects of GSK591, OICT-9429 and JQ1 (Figure 6a ), while UNC0638
and UNC1999 displayed off-target or scaffold effects.
DISCUSSION
Targeting B cells and their differentiation into antibody-producing plasmablasts could constitute a promising treatment strategy for autoimmune diseases [8] . In this study, we intestigated the potential of novel chemical probes targeting epigenetic regualtors and thereby identified novel druggable targets with the potential to modulate B-cell functionality also in B cells from autoimmune patients. The differentiation of mature B cells into antibody-secreting cells occurs through genetic reprogramming [14] involving epigenetic mechanisms shown to be dysregulated in autoimmunity [15] . An abnormal DNA methylation status of SLE B cells points toward the opportunity to target epigenetic regulation for novel therapeutic approaches [16, 17] . In line with this, we find that inhibition of a distinct set of epigenetic regulators reduce the ability of B cells to mature into antibody secreting cells, including those targeting BET, G9a, WDR5, EZH2 and PRMT5.
Our findings point toward epigenetic modulators as important contributors to B-cell maturation.
Studies in other laboratories have shown that the transcription factor B lymphocyte-induced maturation protein 1 (Blimp1) is the master regulator of the terminal differentiation of B cells into antibody secreting cells [18] [19] [20] . The level of Blimp1 expression is regulated by the DNA binding factors Bach2 (BTB and CNC homologue 2) and Bcl6 (B-cell lymphoma 6) [21] , in part by histone acetylation levels [22] . Blimp1 executes its effects by silencing target gene transcription in association with corepressors, including G9a [23] and PRMT5 [24] , which we identify as potential novel targets for future B-cell therapy. In support of our findings, PRMT5, which belongs to the type II protein arginine methyltransferases, has recently been shown to affect germinal center dynamics by regulating the expression of a large number of genes [25] including Bcl6 [26] . Blimp1 is also involved in recruiting histone methylation complex polycomb repressive complex 2 (PRC2), containing the catalytic subunit enhancer or zeste homolog 2 (EZH2) [27] another hit in our screen.
In our test system, a >50% reduction of induced IgG secretion was set as the cutoff for selection of probes to be further studied, based on effects observed with the clinically used positive control, tofacitinib. Interestingly, we found that the probes with effect in our patient-derived cell assays targeted either BET bromodomain containg proteins or HMT methyl transferases. We could also observe differential effects of inhibitors targeting BET compared to HMT on B-cell maturation processes. The HMT inhibitors reduced the proportion of B cells (Figure 3b ), while BET inhibitors JQ1 and PFI-1 did not. This was in part due to inhibition of B-cell proliferation, and in particular the G9a probes UNC0638 and UNC0642 as well as the PRMT5 probe GSK591 effectively blocked proliferation specifically for naïve CD27 -B cells (Figure 4) . Similarly, G9a deficiency in mice results in reduced B-cell proliferation and lower levels of antibodies [28] . G9a functions as a methylator of histone 3, and binds Blimp1 [23] thereby blocking transcriptional repression important in the maturation process of B cells [18] [19] [20] . Contrary to the HMT inhibitors, we show that the BET inhibitors reduced the proportion of CD27 + memory cells (Figure 3b) , and their effect on proliferation was most clearly observed in the CD27 + memory cell compartment ( Figure 4 ) and on cells which had been induced to mature before addition of probes ( Figure 5 ). The importance of BET in B-cell differentiation and antibody production has previously been observed in JQ1 treated mice which show a reduced response to vaccination [29] through ablation of Bcl6 expression.
Moreover, the WD40-repeat protein WDR5 has recently been shown to regulate proliferation of activated B cells [30] , through histone methylation provided by triggering of signals through a KDM4a/KDM4C-WDR5-Cdkn2c/Cdkn3 cascade dysregulated in SLE B cells [30] . Accordingly, we saw a marked reduction in the accumulation of B cells in the presence of WDR5 inhibitor OICR9429 (Figure 3b ), while the effect on proliferation as indicated by Ki67 expression was marginal ( Figure 4 ).
The transcriptional repressor EZH2 is required for maximal antibody secretion [31] and is overexpressed in SLE leukocytes [32] . While we show reduced antibody secretion in presence of the EZH2 inhibitor UNC1999 (Figure 3b ), we see very little effects on proliferation (Figure 4 ) in contrast to other studies [33, 34] . Of note is that the negative control compound for UNC1999, UNC2400, had similar effects as UNC1999 ( Figure 6 ) implicating off-target effects of UNC1999.
We [38] , we found that in vitro stimulation through TLR9 was a main driver of IgG secretion in these assays (Figure 1 ). In summary, although this stimulation protocol represents a model system that may not reflect all fysiological features of B-cell maturation, it captures broad aspects of B-cell biology and provides a highly relevant starting point for further studies.
Importantly, we developed the assay to be compatible with medium throughput (possibly high, depending on the cell source) screening of chemical probes and larger collections using patient derived primary cells. Although this pilot study included a limited number of inhibitors, we are presently developing the protocol into a 384 well plate format to be able to screen up to 200 probes per patient.
This assay has therefore the potential to be used in future personalized medicine strategies for immune mediated diseases.
Since we studied B-cell differentiation in bulk PBMCs, the probe effects detected can be due to direct effects on B cells, or by effects on other cells involved in the maturation of the B cells . To investigate whether the probes directly affect the antibody secreting machinery of already matured B cells, probes were added to PBMCs pre-stimulated for six days ( Figure 5 ). Clearly, the BET inhibiting probes JQ1
and PFI-1 affect the function of the plasmablasts induced using this experimental protocol.
Interestingly, of the five negative control compounds available, two had similar effects compared to the active compounds UNC1999 and UNC0638 ( Figure 6 ). This indicates off-target or scaffold effects of these probes but does not preclude that the effects observed may in part be mediated through inhibition of the target protein. The targets should be further validated in B cells by inhibitors of a distinctly different chemotype and by use of alternative genetic approaches (such as siRNA and CRISPR).
Although B cells from patients with SLE and IIM are phenotypically and functionally different from healthy donors [39] ( Figure 2) , we saw no evident difference of the effects of probes between patients and healthy donors. This could be due to the inter patient differences in response, but also to the stimulation protocol, which induces signaling through several different intracellular pathways, leading to that more subtle differences in responses between cells from patients with autoimmune inflammation and healthy donors are masked. Our experimental platform is also useful for testing and screening of chemical probes' effects on B cells using healthy blood, which makes it useful to research groups not directly linked to rheumatology clinics.
In conclusion, we have developed an assay for screening of novel targets in patient-derived primary cells with a focus on B-cell functions. Using this assay, we have tested the effects of 43 chemical probes and identified compounds with promising inhibitory effects. Inhibition of each target with its designated probe rendered a specific phenotypical/functional cell and potential disease modifying effect. This in turn indicates that specific epigenetic protein targets could be potential new intervention points for future drug discovery and development efforts. IgG ng/mL 
